Josh Gad is the latest celebrity to talk about using a weight loss medication—and while his experience has been positive, he ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion ... weight loss and diabetes drug market. Eli Lilly is developing an obesity pill that would ...

Separately, Eli Lilly said that it expects its new weight loss pill to be approved by U.S. regulators in 2026. The Indianapolis, Indiana-based company said that it will release late-stage trial ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Each expert panellist evaluated the 38 diets and rated each on a scale of one to five. For the “best diet overall” category, diets were judged on nutritional completeness, health risks and ...

The highest-rated episode of Monday Night Raw was on May ... with Triple H emerging as the No. 1 contender and marking the beginning of his rise toward main-event status. An extraordinarily ...

The GLP-1 drug market for weight loss is currently one of the highest growth markets in the world. It is quite likely that the GLP-1 market will reach $150 billion by 2030. 26% of Americans are ...

While it’s too early to rely on supplements, focusing on gut health through a balanced diet rich in fiber, probiotics, and healthy fats could naturally enhance LCA production. Science is still ...